Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 3
Encontrada(s) 1 página(s)

Academica-e. Repositorio Institucional de la Universidad Pública de Navarra
Publicación Artículo científico (JournalArticle)

Circulating TIMP-1 is associated with hematoma volume in patients with spontaneous intracranial hemorrhage

  • Navarro-Oviedo, Manuel
  • Muñoz, Roberto
  • Zandio, Beatriz
  • Marta-Enguita, Juan
  • Bonaterra-Pastra, Anna
  • Rodríguez, José Antonio
  • Roncal Mancho, Carmen
  • Páramo, José A.
  • Toledo, Estefanía
  • Montaner, Joan
  • Hernández-Guillamon, Mar
  • Orbe, Josune
Matrix metalloproteinases (MMPs) are proteolytic zinc-endopeptidases regulated by tissue Inhibitors of matrix metalloproteinases (TIMPs). We evaluated the potential of MMPs and TIMPs as clinical tools for Intracranial Haemorrhage (ICH). Spontaneous non‐traumatic ICH patients were recruited from two hospitals: Complejo Hospitalario de Navarra (CHN = 29) and Vall d´Hebron (VdH = 76). Plasmatic levels of MMP-1, −2, −7, −9, −10 and TIMP-1 and their relationship with clinical, radiological and functional variables were evaluated. We further studied the effect of TIMP-1 (0.05–0.2 mg/Kg) in an experimental tail-bleeding model. In CHN, TIMP-1 was associated with admission-hematoma volume and MMP-7 was elevated in patients with deep when compared to lobar hematoma. In VdH, admission-hematoma volume was associated with TIMP-1 and MMP-7. When data from both hospitals were combined, we observed that an increase in 1 ng/ml in TIMP-1 was associated with an increase of 0.14 ml in haemorrhage (combined β = 0.14, 95% CI = 0.08–0.21). Likewise, mice receiving TIMP-1 (0.2 mg/Kg) showed a shorter bleeding time (p < 0.01). Therefore, the association of TIMP-1 with hematoma volume in two independent ICH cohorts suggests its potential as ICH biomarker. Moreover, increased TIMP-1 might not be sufficient to counterbalance MMPs upregulation indicating that TIMP-1 administration might be a beneficial strategy for ICH., This work was supported by the Ministerio de Economía y Competitividad, Instituto de Salud Carlos III [PI15/01807, PI19/00065] and Federal Ministry of Education and Research (FEDER) funds; grants from the Spanish Society of Thrombosis and Haemostasis (SETH), Navarra Government (02/2015), Patrimonio Praga (Mexico) and Virto Group (Navarra, Spain); and a PhD scholarship from the Asociación de Amigos de la Universidad de Navarra (ADA).
Academica-e. Repositorio Institucional de la Universidad Pública de Navarra
Publicación Artículo científico (JournalArticle)

CM-352 efficacy in a mouse model of anticoagulant-associated intracranial hemorrhage

  • Navarro-Oviedo, Manuel
  • Marta-Enguita, Juan
  • Roncal Mancho, Carmen
  • Rodríguez, José Antonio
  • Zandio, Beatriz
  • Lecumberri, Ramón
  • Hermida, José
  • Oyarzabal, Julen
  • Pineda Lucena, Antonio
  • Páramo, José A.
  • Muñoz, Roberto
  • Orbe, Josune
Background Intracranial hemorrhage (ICH) is one of the major devastating complications of anticoagulation. Matrix metalloproteinase (MMP) inhibition has been proposed as a novel pharmacological approach for ICH treatment. Objectives We evaluated the effects of CM-352 (MMP-fibrinolysis inhibitor) in an experimental ICH model associated with oral anticoagulants as compared with clinically used prothrombin complex concentrate (PCC). Methods ICH was induced by collagenase injection into the striatum of wild type (C57BL/6J) anticoagulated mice (warfarin or rivaroxaban) and Mmp10 −/− mice. Hematoma volume and neurological deficits were measured 24 hours later by diaminobenzidine staining and different behavioral tests. Circulating plasminogen activator inhibitor-1 (PAI-1) activity and interleukin-6 (IL-6) were measured in plasma samples and local inflammation was assessed by neutrophil infiltration. Finally, fibrinolytic effects of MMP-10 and rivaroxaban were evaluated by thromboelastometry and thrombin-activatable fibrinolysis inhibitor (TAFI) activation assays. Results Only PCC reduced hemorrhage volume and improved functional outcome in warfarin-ICH, but both PCC and CM-352 treatments diminished hemorrhage volume (46%, p < 0.01 and 64%, p < 0.001, respectively) and ameliorated functional outcome in rivaroxaban-ICH. We further demonstrated that CM-352, but not PCC, decreased neutrophil infiltration in the hemorrhage area at 24 hours. The effect of CM-352 could be related to MMP-10 inhibition since Mmp10 −/− mice showed lower hemorrhage volume, better neurological score, reduced IL-6 levels and neutrophil infiltration, and increased PAI-1 after experimental ICH. Finally, we found that CM-352 reduced MMP-10 and rivaroxaban-related fibrinolytic effects in thromboelastometry and TAFI activation. Conclusion CM-352 treatment, by diminishing MMPs and rivaroxaban-associated fibrinolytic effects, might be a novel antihemorrhagic strategy for rivaroxaban-associated ICH., This work was supported by ISCIII (PI15/01807 and PI19/00065¿), co-funded by ERDF, ¿A way to make Europe¿, the Spanish Society of Thrombosis and Haemostasis (SETH), the Navarra Government (02/2015), and the Virto Group (Navarra, Spain).
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

MAP7 and MUCL1 are biomarkers of Vitamin D3-induced tolerogenic dendritic cells in multiple sclerosis patients

  • Navarro-Barriuso, Juan|||0000-0003-2884-4961
  • Mansilla Lopez, Maria Jose|||0000-0002-5044-6313
  • Quirant, Bibiana|||0000-0002-3875-8074
  • Ardiaca-Martínez, Alicia
  • Teniente Serra, Aina|||0000-0003-3440-804X
  • Presas Rodríguez, Sílvia|||0000-0001-8545-2476
  • Ten Brinke, Anja
  • Ramo-Tello, Cristina|||0000-0001-8643-5053
  • Martínez Cáceres, Eva María|||0000-0002-6762-8025
The administration of autologous tolerogenic dendritic cells (tolDC) has become a promising alternative for the treatment of autoimmune diseases, such as multiple sclerosis (MS). Specifically, the use of vitamin D3 for the generation of tolDC (vitD3-tolDC) constitutes one of the most widely studied approaches, as it has evidenced significant immune regulatory properties, both in vitro and in vivo. In this article, we generated human vitD3-tolDC from monocytes from healthy donors and MS patients, characterized in both cases by a semi-mature phenotype, secretion of IL-10 and inhibition of allogeneic lymphocyte proliferation. Additionally, we studied their transcriptomic profile and selected a number of differentially expressed genes compared to control mature and immature dendritic cells for their analysis. Among them, qPCR results validated CYP24A1, MAP7 and MUCL1 genes as biomarkers of vitD3-tolDC in both healthy donors and MS patients. Furthermore, we constructed a network of protein interactions based on the literature, which manifested that MAP7 and MUCL1 genes are both closely connected between them and involved in immune-related functions. In conclusion, this study evidences that MAP7 and MUCL1 constitute robust and potentially functional biomarkers of the generation of vitD3-tolDC, opening the window for their use as quality controls in clinical trials for MS.